. Author manuscript; available in PMC: 2013 Sep 25.

Published in final edited form as: Eur J Radiol. 2011 Jun 8;81(8):1702–1706. doi: 10.1016/j.ejrad.2011.04.067

Table 1.

Mean dose length product and effective dose during CT-guided percutaneous cryoablation of liver tumors (n = 20).

Procedural phases	Dose length product (mGy*cm)		Effective dose (mSv)
	Mean±SD	Range	Mean±SD	Range
Planning	322 ± 150	138–681	4.8 ± 2.2	2–10
Targeting	2496 ± 843	1662–4492	37.5 ± 12.5	25–67
Monitoring	1706 ± 454	937–2825	25.5 ± 6.8	14–42
Post-ablation survey	273 ± 123	135–548	4.1 ± 1.9	2–8
Entire procedure	4796 ± 1214	3059–7784	72 ± 18	46–117

Note: SD, standard deviation. Dose length product and effective dose for each phase were significantly different from each other (p < 0.0001) except for the planning and post-ablation survey phases (p > 0.05).